Repare Therapeutics is using the concept of synthetic lethality to develop novel medicines in oncology. Synthetic lethality refers to cases where perturbations in two targets results in death, while perturbations in either one is viable. Repare is using their innovative SNIPRx platform that uses CRISPR-screening technology to identify novel synthetic lethality targets against clinically relevant genomic alterations in tumors. Once targets are selected, Repare can then design selective small molecule inhibitors of these targets. Currently, Repare has advanced a robust clinical pipeline with their lead program, RP-6306, in clinical trials.

Repare Therapeutics

Founded: 2016
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: Clin1/Clin2
Therapy area: Solid tumors
Drug types: ONC
Lead product: Camonsertib (partner: Roche)
Funding: $253M IPO Jun 2020; $82.5M B Sep 2019; $68M A Jun 2017

Drug notes:

About:

Jobs: